SBIR/STTR Research Award
Reversing Isoniazid Resistance By Isotopic Substitution
Award amount
$1,188,095Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SpinCeutica, Inc.
- Proposal award date
- 2017-03-06
- Contract end date
- 2020-02-29
- UEI
- VDTKVZHN6P79
- Solicitation number
- PAR14-088
- Topic code
- NIAID
Research abstract
Project Summary
The overall goal of this project is to develop our new stable isotope labeledversion of an
existing tuberculosisTBdrugisoniazidINHfor use in treated drug resistant TBWe
hypothesize that our that isotope enhanced compound can be developed into a powerful new
drug against INH resistant TB and multidrug resistant TBby addressing the following specific
aimsSpecific AimDetermine what other INH resistance associated mutationsacylC INH can
overcomeand determine the mechanism for whyacylC INH overcomes the high INH
resistance of mutant ST KatG strainsSpecific AimDevelop an optimized synthesis of our compound and a Technology Transfer
ProtocolTTPfor external good manufacturing processesGMP capable manufactureSpecific AimCollect non Good Laboratory PracticesGLPtoxicology data on our
compound to support subsequent GLP Investigational New DrugINDenabling studiesSuccessful completion of these tasks will pave the way for venture capital funding and transfer
of our compound into clinical testing
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Rifampin potentiation in NTM
- Overcoming Isoniazid Resistance in Tuberculosis with New Chemical Entitites
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
3 SBIR/STTR records share this UEI (2017–2020). Reported award amounts total $1,580,894. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services